You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Emodin as a complementary dietary therapy to reduce toxicity of 5 fluorouracil
SBC: AcePre, LLC Topic: NCCIHPROJECT SUMMARYfluorouracilFUhas been the first choice chemotherapy drug for colorectal cancerCRCfor many yearshoweverits clinical utility remains hindered by hematopoietic and gastrointestinal toxicities resulting from its non selectivitySide effects include fatigueloss of appetiteand diarrhea among othersall of which can lead to reduced quality of lifeThe economic burden associated with chemothe ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Mitigating Injurious Falls in Older Adults Through Non-Injurious Fall and Gait Analysis From Floor Vibrations
SBC: ADVANCED SMART SYSTEMS AND EVALUATION TECHNOLOGIES, LLC Topic: NIAProject Summary and Abstract Falls are the leading cause of death due to injuryThis simple motion is so common thatof community dwelling older adultsandof long term care facilities will experience a fall in the coming yearThe risk of falling substantially increases for those having Alzheimer s disease and related dementiasand those with Parkinson s diseaseThe financial burden is significant with f ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Targeted Nanotherapy to Donor Organ Endothelia Modulates Early Immune Responses and Protects Against Late Graft Failure
SBC: ToleRaM NanoTech LLC Topic: NIBIBABSTRACT Transplantation is an accepted and highly successful therapy for end stage organ diseaseWhile success rates and survival have risen steadilydue largely to improved immunosuppression regimesthere is a growing appreciation that damage and inflammation that occur early in the life of the graftsignificantly impact chronic rejection and thus long term survivalCentral to these early event injur ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Therapeutic Inhibition of BCL6 in Systemic Lupus Erythematosus
SBC: L2 DIAGNOSTICS LLC Topic: NIAMSABSTRACT Systemic autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus are characterized by polyclonal T cell activation driving the production of pathogenic class switched autoantibodiesThe class switchedsomatically mutated antibodies are generated from germinal centerGCB cellsA subset of effector CDT cellsknown as T follicular helperTfhcellshas been shown to play an ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Development of a Point of Care Diagnostic Screening test for Kawasaki disease
SBC: L2 DIAGNOSTICS LLC Topic: NICHDABSTRACT Kawasaki DiseaseKDis a febrile childhood vasculitis with potentially catastrophic clinical outcomesUntreatedone in five children develop coronary artery aneurysms causing significant morbidity and mortalityTypical KD presents as a febrile illness andgtdays in children andltyears oldThere are no diagnostic tests for KDit is diagnosed clinically based on a fever andgtdays with at leastofphy ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Artificial Salivary Gland Dental Implant
SBC: ORAL FLUID DYNAMICS LLC Topic: NIDCRXerostomiaor dry mouthaffects approximatelyof the U Spopulationsomemillion people by causing oral discomfort and pain due to chronically dry mucosaThis condition leads to oral disease such as caries and candidiasisand has no cure or adequate treatmentMany remedial approaches have been tried with only limited successincluding the provision of fluid to the mouth via frequent sippingvarious mouthwash ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
A Method to Increase Buprenorphine Treatment Capacity and Effectiveness
SBC: CBT4CBT LLC Topic: R42The goal of this fast track STTR proposal is to expand buprenorphine maintenance therapy for opioiddependent patientsOvermillion people in the US are addicted to opiatesProviding effective agonist therapymethadone or buprenorphinecoupled with behavioral counseling greatly improves outcomesreduces morbidityand reduces societal costsMethadone maintenance treatment has been limited due to complex sta ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Bifunctional Regenerative Electrochemical Air Transformation for Human Environments
SBC: SKYRE, INC Topic: T6The proposed Bifunctional Regenerative Electrochemical Air Transformation for Human Environments (BREATHE) for life support and habitation is part of the atmosphere revitalization equipment necessary to provide and maintain a livable environment within the pressurized cabin of crewed spacecraft. Sustainable Innovations (SI) has developed a novel solid state technology for gas compression based on ...
STTR Phase I 2018 National Aeronautics and Space Administration -
A Novel Treatment for Acetominophen-Induced Liver Injury
SBC: MITOTHERAPEUTIX, LLC Topic: 300Abstract The Specific Aim of this Phase I STTR proposal is to test the feasibility of blocking MCJalso called DnaJCto overcome acute acetaminophen liver toxicityAcetaminophen or APAPfrom acetyl paraaminophenolis a common drug used to address pain and feverIn the US aloneaboutpatients per year are admitted to intensive care units with APAP induced liver injury and close toof these patients undergo ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma
SBC: LEUKOGENE THERAPEUTICS INC Topic: 102Project Summary Abstract Multiple MyelomaMMis the second most common form of blood cancer and remains an incurable and deadly diseaseProteasome inhibitorPItherapy is a cornerstone in the treatment of MMbut resistance to this class of agent is an emerging challenge in the clinicNew therapeutic approaches that specifically target resistance are needed to maximize responses and ultimately produce cur ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health